Interferon alfa-2b

Generic Medicine Info
Hypersensitivity. Hepatic decompensation, autoimmune hepatitis or a history of autoimmune disease, immunosuppressed transplant recipients.
Special Precautions
History of pulmonary disease (e.g. COPD) or DM prone to ketoacidosis. Coagulation disorders or severe myelosuppression. Monitor patients with history of MI and/or arrhythmic disorders. Preexisting or history of psychiatric disorder, particularly depression. Poorly controlled thyroid abnormalities. Perform ophthalmological exam on patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy). Monitor WBC count in myelosuppressed patients and in those receiving other myelosuppressive agents. Preexisting psoriasis. May impair ability to drive or operate machinery. Pregnancy and lactation.
Adverse Reactions
Flu-like symptoms; alopecia; hypersensitivity reactions; nausea; anorexia; myelosuppression; lethargy; ocular side effects; depression; CV problems; nephrotoxicity; hypertriglyceridaemia; thyroid abnormalities; hyperglycaemia; psoriasiform rash; confusion; coma; seizures.
Potentially Fatal: Hepatotoxicity, pulmonary infiltrates, pneumonitis and pneumonia, autoimmune diseases.
ROUTE(S) : Intralesional: X when used in combination w/ ribavirin
ROUTE(S) : IM / IV / Parenteral / SC: X when used in combination w/ ribavirin.
Drug Interactions
Reduces clearance of theophylline. Enhanced myelosuppression with other myelosuppressive drugs (e.g. zidovudine).
ATC Classification
L03AB05 - interferon alfa-2b ; Belongs to the class of interferons. Used as immunostimulants.
Disclaimer: This information is independently developed by CIMS based on interferon alfa-2b from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in